Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Trump to impose tariffs of 100% on branded drug imports

(Sharecast News) - Donald Trump is to impose tariffs of 100% on imports of pharmaceutical goods, it emerged on Friday, the latest salvo in the US president's global trade war. Posting on Truth Social, Trump said the levies would be imposed on any branded or patented pharmaceutical product from 1 October.

However, drugs companies could be exempt if they are already building manufacturing facilities in the US.

"There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started," he wrote "Thank you for your attention to this matter!"

A number of pharmaceutical companies worldwide - including AstraZeneca and GSK - have recently announced major US investment plans, in light of long-threatened tariffs on the sector. However, construction may not have started, due to the complex nature of manufacturing across the sector.

The Social Media post was one of several updates on tariffs made by the president early on Friday morning.

He announced a separate 50% tariff on imports of kitchen cabinets and bathroom vanities, also starting from 1 October, and a 30% tax on upholstered furniture.

"The reason for this is the large scale 'FLOODING' of these products into the United States by other outside Countries," he wrote.

In addition, Trump said "all heavy (big!) trucks" made outside of America will be subject to a 25% import charge, to protect US manufacturers from "the onslaught of outside interruptions".

Kathleen Brooks, research director at XTB, said: "This is a reminder that Trump's tariffs are never finished. When we think we can move on from the threat of tariffs, they raise their head once more. The next set of tariffs could be directed at semiconductors and critical rare earth minerals in a number of weeks."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.